Is GlaxoSmithKline plc about to bomb?

Could shares in GlaxoSmithKline plc (LON: GSK) be about to suffer a major fall?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In recent years, GlaxoSmithKline (LSE: GSK) has been a major disappointment for its investors. Its share price has slumped by 12% in the last three years as bribery allegations, the loss of patents on key drugs, and a lack of sufficient replacements have come together to hurt the company’s top and bottom lines. And while GlaxoSmithKline’s shares may have outperformed the FTSE 100 in the last year, they are still down by around 4% during the period.

The anticipation of improved profitability

As a result of this, many investors may feel that GlaxoSmithKline is a stock to avoid at the present time. However, this does not appear to be justified, with the diversified health care stock reporting a very encouraging set of results recently which showed that it has stunning long term potential. For example, it’s experiencing strong sales and profit growth, and is on-track to report higher growth figures than many of its peers and the wider index.

In fact, GlaxoSmithKline is expected to reverse four years of earnings declines by posting a rise in its bottom line of 16% in the current year, followed by a rise in net profit of 4% next year. Although earnings per share will still be well below their 2011 level even after such impressive growth, the key takeaway is that investor sentiment could begin to improve due to a step change in GlaxoSmithKline’s financial performance. And, as history shows, the anticipation of improved profitability can often lead to sharper share price gains than the actual reporting of such profits.

Clearly, rising profitability is excellent news for GlaxoSmithKline’s dividend and while it is set to be held at its current level over the next couple of years, in the long run there is considerable scope for a sustained rise in shareholder payouts.

An excellent defensive profile

That’s largely because of the strength of GlaxoSmithKline’s vaccine division, as well as an impressive pipeline within its pharmaceutical division, which includes exciting new treatments in the ViiV Healthcare segment. They have the potential to make a huge difference to sales and profitability, while GlaxoSmithKline’s consumer goods offering should provide relatively stable and consistent returns, too. GlaxoSmithKline’s yield of 5.5% is high and could benefit from a rapidly rising dividend over the medium to long term.

As well as offering sound financial performance, GlaxoSmithKline also offers an excellent defensive profile. As alluded to, it is not a pure play pharmaceutical company and so its bottom line could prove to be much more robust than some of its sector peers.

Furthermore, GlaxoSmithKline is not highly dependent upon the business cycle, which means that during periods of economic uncertainty its shares could become increasingly popular among investors. With an EU referendum and US election due over the coming months, GlaxoSmithKline’s share price could therefore soar, rather than bomb.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »